Sierra Oncology (SRRA) Receives a Rating Update from a Top Analyst


In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Sierra Oncology (SRRA), with a price target of $29.00. The company’s shares closed last Friday at $18.33.

According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 36.9% and a 60.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.

Sierra Oncology has an analyst consensus of Strong Buy, with a price target consensus of $34.67.

See today’s analyst top recommended stocks >>

Based on Sierra Oncology’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $19.92 million. In comparison, last year the company had a GAAP net loss of $31.91 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of patients with cancer. It engages in the business of researching, developing, and commercializing therapies for the treatment of patients with cancer. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts